Studies have shown that after methylation of CpG islands in the SOCS3 promoter region, SOCS3 gene silencing, and mRNA expression decreased, which was predictive of adverse clinical outcomes and prognosis, such as GBM (33–35). Here, SOCS3 is linked to glioblastoma.